Table 2. WHOQOL-BREF questionnaire assessment outcome for the treatment and placebo group at baseline and end of therapy.

CI, confidence interval

		Ashwagandha						Placebo
	N	Mean	SD	95% C.I.			N	Mean	SD	95% CI
				Lower	Upper					Lower		Upper
Baseline
Total Score	19	140.53	8.25	124.36		156.70	20	139.3	9.65	120.39	158.21
Global domain	19	8.26	0.93	6.44		10.08	20	8.05	0.89	6.31	9.79
Physical domain	19	36.11	4.81	26.68		45.54	20	36.9	3.04	30.94	42.86
Psychological domain	19	32.05	3.36	25.46		38.64	20	31.15	2.62	26.01	36.29
Social relationship domain	19	27.16	2.79	21.69		32.63	20	27	1.97	23.14	30.86
Environment domain	19	36.95	5.02	27.11		46.79	20	36.2	4.4	27.58	44.82
End of therapy (12 weeks)
Total Score	19	161.84***	9.32	143.57		180.11	20	147.65	10.5	127.07	168.23
Global domain	19	10.26 ***	0.93	8.44		12.08	20	9.05	0.89	7.31	10.79
Physical domain	19	44.21***	3.01	38.31		50.11	20	39.75	3.35	33.18	46.32
Psychological domain	19	38.11***	2.23	33.74		42.48	20	33.45	2.58	28.39	38.51
Social relationship domain	19	28.68	2.14	24.49		32.87	20	28.2	2.07	24.14	32.26
Environment domain	19	40.58 *	3.96	32.82		48.34	20	37.2	4.4	28.58	45.82
* and *** indicates p < 0.05 and p < 0.0001 respectively for a two-tailed T-test for improvement from baseline being higher than the placebo.